KF
RARE icon

Krilogy Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Krilogy Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Buy
+11,941
New +$297K 0.01% 718
2018
Q2 		– Sell
-100
Closed -$5K – 513
2018
Q1 		$5K Hold
100
– – ﹤0.01% 602
2017
Q4 		$5K Hold
100
– – ﹤0.01% 604
2017
Q3 		$5K Hold
100
– – ﹤0.01% 657
2017
Q2 		$6K Buy
+100
New +$6.03K ﹤0.01% 582

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Krilogy Financial's RARE Position: Q2 2026 in Review

Krilogy Financial opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 11,941 shares worth $399K. The stake represents 0.01% of the portfolio and ranks #718 among its holdings. This is a return to the name: Krilogy Financial previously reported a position in RARE as recently as Q1 2018.

Krilogy Financial first reported a position in RARE in Q2 2017 and has held it in 5 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Krilogy Financial held 11,941 shares of Ultragenyx Pharmaceutical worth $399K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Krilogy Financial position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.01% of Krilogy Financial's portfolio in Q2 2026, its #718 holding.
  • Krilogy Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and has held it in 5 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.